A Goldhirsch
Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?
Coates A, Goldhirsch A, Gelber R, Ingle J, Thürlimann B, Senn H. Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?. Ann Oncol 2019; 20:1751-1752.
Dec 4, 2019Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?
Dec 4, 2019Ann Oncol 2019; 20:1751-1752
Coates A S, Goldhirsch A, Gelber R D, Ingle J N, Thürlimann Beat, Senn H-J
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT
Regan M, Goldhirsch A, Coates A, Gelber R, Abdi E, Ruhstaller T, Parmar V, Spazzapan S, Salim M, Pinotti G, Tondini C, Colleoni M, Gómez H, Láng I, Fleming G, Francis P, Walley B, Pagani O. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 2017; 28:2225-2232.
Sep 1, 2017Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT
Sep 1, 2017Ann Oncol 2017; 28:2225-2232
Regan M M, Goldhirsch A, Coates A S, Gelber R D, Abdi E A, Ruhstaller Thomas, Parmar V, Spazzapan S, Salim M, Pinotti G, Tondini C, Colleoni M, Gómez H L, Láng I, Fleming G F, Francis P A, Walley B A, Pagani O
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99
Pagani O, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, Moos R, Zaman K, Goldhirsch A, Pestalozzi B, Munzone E, Klingbiel D, Ruhstaller T, Nolé F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99. Ann Oncol 2016
Dec 19, 2016Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99
Dec 19, 2016Ann Oncol 2016
Pagani O, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann Beat, Moos R von, Zaman K, Goldhirsch A, Pestalozzi B, Munzone E, Klingbiel D, Ruhstaller Thomas, Nolé F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess Dagmar, Mamot C
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial
Munzone E, Colleoni M, Goldhirsch A, Coates A, Gelber R, Price K, Lelkaitis G, Bibeau F, Macgrogan G, Ejlertsen B, Thürlimann B, Viale G, Mallon E, Gusterson B, Giobbie-Hurder A, International Breast Cancer Study Group and the BIG 1-98 Collaborative Group. Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. Ann Oncol 2015
Sep 19, 2015Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial
Sep 19, 2015Ann Oncol 2015
Munzone E, Colleoni M, Goldhirsch A, Coates A S, Gelber R D, Price K N, Lelkaitis G, Bibeau F, Macgrogan G, Ejlertsen B, Thürlimann Beat, Viale G, Mallon E, Gusterson B A, Giobbie-Hurder A, International Breast Cancer Study Group and the BIG 1-98 Collaborative Group
-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
Coates A, Winer E, Goldhirsch A, Gelber R, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn H, Panel members. -Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015; 26:1533-46.
May 4, 2015-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
May 4, 2015Ann Oncol 2015; 26:1533-46
Coates A S, Winer E P, Goldhirsch A, Gelber R D, Gnant M, Piccart-Gebhart M, Thürlimann Beat, Senn H-J, Panel members
Symptoms of endocrine treatment and outcome in the BIG 1-98 study
Huober J, Thürlimann B, Gelber R, Colleoni M, Coates A, Goldhirsch A, Price K, Wardley A, Smith I, Láng I, Neven P, Forbes J, Bonnefoi H, Ejlertsen B, Wu J, Giobbie-Hurder A, Rabaglio M, Cole B, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat 2013; 143:159-69.
Dec 5, 2013Symptoms of endocrine treatment and outcome in the BIG 1-98 study
Dec 5, 2013Breast Cancer Res Treat 2013; 143:159-69
Huober J, Thürlimann Beat, Gelber R D, Colleoni M, Coates A S, Goldhirsch A, Price K N, Wardley A, Smith I, Láng I, Neven P, Forbes J F, Bonnefoi H, Ejlertsen B, Wu J, Giobbie-Hurder A, Rabaglio M, Cole B F, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Goldhirsch A, Winer E, Coates A, Gelber R, Piccart-Gebhart M, Thürlimann B, Senn H, Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24:2206-23.
Aug 4, 2013Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Aug 4, 2013Ann Oncol 2013; 24:2206-23
Goldhirsch A, Winer E P, Coates A S, Gelber R D, Piccart-Gebhart M, Thürlimann Beat, Senn H-J, Panel members
Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report
Karlsson P, Gruber G, Goldhirsch A, Gelber R, Forbes J, Castiglione-Gertsch M, Crivellari D, Thürlimann B, Kovács A, Collins J, Lindtner J, Price K, Chua B, Cole B, International Breast Cancer Study Group. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. Ann Oncol 2012; 23:2852-8.
Jul 9, 2012Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report
Jul 9, 2012Ann Oncol 2012; 23:2852-8
Karlsson P, Gruber G, Goldhirsch A, Gelber R D, Forbes J F, Castiglione-Gertsch M, Crivellari D, Thürlimann Beat, Kovács A, Collins J P, Lindtner J, Price K N, Chua B H, Cole B F, International Breast Cancer Study Group
Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials
Huober J, Regan M, Gelber R, Price K, Öhlschlegel C, Viale G, Coates A, Goldhirsch A, Gelber S, Thürlimann B. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol 2012; 23:2843-51.
Jun 14, 2012Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials
Jun 14, 2012Ann Oncol 2012; 23:2843-51
Huober Jens, Regan M M, Gelber R D, Price K N, Öhlschlegel Christian, Viale G, Coates A S, Goldhirsch A, Gelber S, Thürlimann Beat
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
Ribi K, BIG 1-98 Collaborative Group, Bernhard J, Gelber R, Price K, Goldhirsch A, Coates A, Pagani O, Cardoso F, Thürlimann B, Harvey V, Thompson A, Phillips K, Aldridge J, International Breast Cancer Study Group. Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. Br J Cancer 2012; 106:1618-25.
Apr 24, 2012Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
Apr 24, 2012Br J Cancer 2012; 106:1618-25
Ribi K, BIG 1-98 Collaborative Group, Bernhard J, Gelber R D, Price K N, Goldhirsch A, Coates A S, Pagani O, Cardoso F, Thürlimann Beat, Harvey V, Thompson A, Phillips K-A, Aldridge J, International Breast Cancer Study Group
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
Goldhirsch A, Wood W, Coates A, Gelber R, Thürlimann B, Senn H, Panel members. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22:1736-47.
Jun 27, 2011Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
Jun 27, 2011Ann Oncol 2011; 22:1736-47
Goldhirsch A, Wood W C, Coates A S, Gelber R D, Thürlimann Beat, Senn H-J, Panel members
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
Viale G, Thürlimann B, Mouridsen H, Mauriac L, Gelber R, Price K, Goldhirsch A, Gusterson B, Coates A, Láng I, Colleoni M, Regan M, Dell'orto P, Mastropasqua M, Maiorano E, Rasmussen B, Macgrogan G, Forbes J, Paridaens R, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 2011; 22:2201-2207.
Feb 18, 2011Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
Feb 18, 2011Ann Oncol 2011; 22:2201-2207
Viale G, Thürlimann Beat, Mouridsen H, Mauriac L, Gelber R D, Price K N, Goldhirsch A, Gusterson B A, Coates A S, Láng I, Colleoni M, Regan M M, Dell'orto P, Mastropasqua M G, Maiorano E, Rasmussen B B, Macgrogan G, Forbes J F, Paridaens R J, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
Rabaglio M, Coates A, Goldhirsch A, Gelber R, Smith I, Láng I, Nogaret J, Pienkowski T, Colleoni M, Paridaens R, Forbes J, Campone M, Mouridsen H, Thürlimann B, Hawle H, Castiglione-Gertsch M, Price K, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009; 20:1489-98.
Sep 1, 2009Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
Sep 1, 2009Ann Oncol 2009; 20:1489-98
Rabaglio M, Coates A S, Goldhirsch A, Gelber R D, Smith I, Láng I, Nogaret J-M, Pienkowski T, Colleoni M, Paridaens R J, Forbes J F, Campone M, Mouridsen H, Thürlimann Beat, Hawle H, Castiglione-Gertsch M, Price K N, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
Goldhirsch A, Ingle J, Gelber R, Coates A, Thürlimann B, Senn H, Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20:1319-29.
Aug 1, 2009Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
Aug 1, 2009Ann Oncol 2009; 20:1319-29
Goldhirsch A, Ingle J N, Gelber R D, Coates A S, Thürlimann Beat, Senn H-J, Panel members
The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up
Colleoni M, Goldhirsch A, Price K, Viale G, Aebi S, Cinieri S, Peccatori F, Green M, Gelber R, Coates A, Basser R, Martinelli G, Sun Z, International Breast Cancer Study Group. The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol 2009; 20:1344-51.
Aug 1, 2009The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up
Aug 1, 2009Ann Oncol 2009; 20:1344-51
Colleoni M, Goldhirsch A, Price K N, Viale G, Aebi S, Cinieri S, Peccatori F, Green M D, Gelber R D, Coates A S, Basser R L, Martinelli G, Sun Z, International Breast Cancer Study Group
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer
Viale G, Goldhirsch A, Gelber R, Öhlschlegel C, Karlsson P, Crivellari D, Golouh R, Brown R, Price K, Regan M, Castiglione-Gertsch M, Colleoni M, Mallon E, Sonzogni A, Mastropasqua M, Maiorano E, Gusterson B, Giobbie-Hurder A, Coates A. Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Ann Oncol 2009; 21:245-54.
Jul 24, 2009Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer
Jul 24, 2009Ann Oncol 2009; 21:245-54
Viale G, Goldhirsch A, Gelber R D, Öhlschlegel Christian, Karlsson P, Crivellari D, Golouh R, Brown R W, Price K N, Regan M M, Castiglione-Gertsch M, Colleoni M, Mallon E, Sonzogni A, Mastropasqua M G, Maiorano E, Gusterson B A, Giobbie-Hurder A, Coates A S
Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer
Gruber G, Gusterson B, Viale G, Goldhirsch A, Price K, Coates A, Gelber R, Fey M, Simoncini E, Thürlimann B, Crivellari D, Collins J, Golouh R, Lindtner J, Holmberg S, Castiglione-Gertsch M, Cole B, International Breast Cancer Study Group. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Ann Oncol 2008; 19:1393-401.
Aug 1, 2008Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer
Aug 1, 2008Ann Oncol 2008; 19:1393-401
Gruber G, Gusterson B A, Viale G, Goldhirsch A, Price K N, Coates A S, Gelber R D, Fey M F, Simoncini E, Thürlimann Beat, Crivellari D, Collins J, Golouh R, Lindtner J, Holmberg S B, Castiglione-Gertsch M, Cole B F, International Breast Cancer Study Group
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
Regan M, SOFT/TEXT/PERCHE Steering Committee, Gelber R, Goldhirsch A, Coates A, Castiglione-Gertsch M, Maibach R, Thürlimann B, Price K, Fleming G, Francis P, Perez E, Torrisi R, Walley B, Pagani O, International Breast Cancer Study Group. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. Ann Oncol 2008; 19:1231-41.
Jul 1, 2008Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
Jul 1, 2008Ann Oncol 2008; 19:1231-41
Regan M M, SOFT/TEXT/PERCHE Steering Committee, Gelber R D, Goldhirsch A, Coates A S, Castiglione-Gertsch M, Maibach R, Thürlimann Beat, Price K N, Fleming G F, Francis P, Perez E A, Torrisi R, Walley B, Pagani O, International Breast Cancer Study Group
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
Bernhard J, Coates A, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Colleoni M, Green M, Thürlimann B, Yeo W, Aebi S, Forbes J, Hürny C, Basser R, Martinelli G, Zhang J, Zahrieh D, International Breast Cancer Study Group. Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. BJC 2008; 98:25-33.
Jan 15, 2008Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
Jan 15, 2008BJC 2008; 98:25-33
Bernhard J, Coates A S, Goldhirsch A, Price K N, Castiglione-Gertsch M, Gelber R D, Colleoni M, Green M D, Thürlimann Beat, Yeo W, Aebi S, Forbes J F, Hürny C, Basser R, Martinelli G, Zhang J J, Zahrieh D, International Breast Cancer Study Group
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
Goldhirsch A, Wood W, Gelber R, Coates A, Thürlimann B, Senn H, 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18:1133-44.
Jul 1, 2007Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
Jul 1, 2007Ann Oncol 2007; 18:1133-44
Goldhirsch A, Wood W C, Gelber R D, Coates A S, Thürlimann Beat, Senn H-J, 10th St. Gallen conference